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The cellular origins of fibrosis in different
tissues are unclear. Kramann et al. show
that Gli1 marks a network of perivascular
mesenchymal-stem-cell-like cells that
generate myofibroblasts and play a
central role in organ fibrosis after injury,
and ablating these cells ameliorates
fibrosis and rescues organ function.
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Mesenchymal stem cells (MSCs) reside in the peri-
vascular niche of many organs, including kidney,
lung, liver, and heart, although their roles in these
tissues are poorly understood. Here, we demon-
strate that Gli1 marks perivascular MSC-like cells
that substantially contribute to organ fibrosis.
In vitro, Gli1+ cells express typical MSC markers,
exhibit trilineage differentiation capacity, and
possess colony-forming activity, despite consti-
tuting a small fraction of the platelet-derived growth
factor-b (PDGFRb)+ cell population. Genetic lineage
tracing analysis demonstrates that tissue-resident,
but not circulating, Gli1+ cells proliferate after kid-
ney, lung, liver, or heart injury to generate myofibro-
blasts. Genetic ablation of these cells substantially
ameliorates kidney and heart fibrosis and preserves
ejection fraction in a model of induced heart failure.
These findings implicate perivascular Gli1+ MSC-like
cells as a major cellular origin of organ fibrosis
and demonstrate that these cells may be a relevant
therapeutic target to prevent solid organ dysfunc-
tion after injury.
INTRODUCTION
More than half a century ago it was noted that subcutaneously
implanted bone marrow cells could form bone (Danis, 1957).
Once isolated, the cell type responsible for this effect was
termed mesenchymal stem cells (MSCs) in reference to multi-
potent cells within bone marrow capable of giving rise to
mesenchymal tissues (Caplan, 1991). These MSCs possess
stem cell characteristics including self-renewal and clonogenic
capacity (Caplan and Correa, 2011). In recent years MSCs have
been isolated from virtually all postnatal and fetal tissues,
including placenta, adipose tissue, muscle, umbilical cord,
skin, dental pulp, and tendon, and have been characterized
in vitro (Murray et al., 2014). Vasculature represents the in vivoniche of MSCs, helping to explain why MSCs have such a
broad tissue distribution (Crisan et al., 2008). However, our cur-
rent knowledge about MSCs is almost entirely based on in vitro
observations of cultured MSCs. The term MSC-like is used to
refer to cells in vivo that are perivascular and give rise to typical
cultured MSCs that possess trilineage differentiation potential,
a defined surface marker expression pattern, and a spindle-
shaped appearance. MSC-like cells localize to the pericyte
niche in microvasculature, where they make close contact to
endothelial cells (ECs), and they also reside in the adventitia
of larger vessels, where they are embedded in matrix and do
not contact endothelia (Murray et al., 2014).
Exogenously infused MSCs modulate tissue injury and repair,
largely through paracrine secretion of antiapoptotic, antiscar-
ring, proangiogenic, and immunomodulatory factors involved
in tissue regeneration (Caplan and Correa, 2011). These proper-
ties have led to novel therapeutic strategies involving exoge-
nous administration of MSCs in various injury and disease
settings. Almost 400 clinical trials involving exogenous MSCs
are ongoing or have been performed (http://www.FDA.gov).
Despite the broad therapeutic potential of this cell type, the
in vivo role of perivascular MSC-like cells remains undefined
due to the absence of specific markers. Recently Zhao et al.
demonstrated that Gli1 is just such a marker of perivascular
MSC-like cells in the mouse incisor (Zhao et al., 2014). Gli1+
incisor cells express typical MSC surface markers in culture
and possess trilineage differentiation capability. Using a Gli1-
CreERt2 genetic fate tracing approach, the authors showed
that after incisor injury newly formed dentin tubules derive
from Gli1+ cells.
We demonstrate that, in mice, perivascular Gli1+ cells
from bone marrow, muscle, heart, lung, liver, and kidney
express a typical MSC marker pattern in vivo, are plastic
adherent, and possess trilineage differentiation capability
toward chondrocytes, osteoblasts, and adipocytes in vitro.
Gli1+ cells form an extensive perivascular network and
possess increased colony forming unit capability. After organ
injury these resident Gli1+ cells are committed to the myofi-
broblast lineage. Genetic ablation of Gli1+ cells ameliorates
fibrosis and improves organ function, providing a proof of
principle for therapeutic targeting of this cell type in fibrotic
disease.Cell Stem Cell 16, 51–66, January 8, 2015 ª2015 Elsevier Inc. 51
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Gli1+ Cells Form an Extensive Network around the
Vasculature, Express a Typical MSC Marker Pattern
In Vivo, and Possess Trilineage Differentiation
Capability In Vitro
While examining expression of Hedgehog (Hh) pathway constit-
uents, we observed that Gli1 is specifically expressed in cells
surrounding vasculature, from microvascular capillaries to large
arteries (Figure S1A available online). The perivascular localiza-
tion and low frequency of these cells suggested a possible
MSC-like identity, similar to the recent report that Gli1 marks
mouse incisor MSCs (Zhao et al., 2014).
To comprehensively assess the distribution of these cells in
solid organs and tissues, we crossed Gli1-CreERt2 driver mice
to a tdTomato reporter for inducible genetic labeling. Gli1-
CreERt2; tdTomato mice were pulsed with tamoxifen at 8 weeks,
and 48 hr later Gli1+ cells were identified in the perivascular niche
across all tissues tested (Figures 1A–1C). Immunostaining for
endogenous Gli1 protein and Gli1 mRNA expression of sorted
cell populations validated this model (Figures S1B and S1C).
Gli1+ cells formed an extensive perivascular network that was
(1) localized in the adventitia of large arteries (Figure 1A) and ar-
terioles (Figure 1C arrows) distant from ECs (adventitial niche)
and (2) intimately associated with the microvasculature in direct
contact to CD31+ ECs (Figure 1C, arrowheads). Immunogold
staining and electron microscopy confirmed that Gli1+ cells lie
directly adjacent to ECs (Figure 1B). Gli1+ cells were also posi-
tioned around biliary ducts of the liver and around larger airways
of the lung (Figure 1C, asterisk). Gli1+ cells consistently ex-
pressed the mesenchymal marker PDGFRb (Figures 1A and
1C). In contrast to mouse incisor wherein Gli1+ cells are predom-
inantly periarterial (Zhao et al., 2014), we found that many Gli1+
cells also exist in a pericyte niche adjacent to ECs of muscle,
bone marrow, lung, heart, kidney, and liver. To better define
the relationship of Gli1+ cells relative to vasculature, we per-
formed fluorescence microangiography (FMA), (Kramann et al.,
2014). This demonstrated very close apposition of Gli1+ cells
around capillaries in both heart and kidney, with tdTomato+
cell processes wrapping around fluorescent microbead filled
capillaries (Movie S1 and Movie S2).
We employed fluorescence-activated cell-sorting (FACS) of
whole digested organs and tissues to define the overall fre-
quency of Gli1+ cells (Figure 1D). To characterize Gli1+ cells by
accepted criteria defined for MSCs, we cultured sorted Gli1+
cells and determined that they had trilineage differentiation
capacity toward chondrocytes, adipocytes, and osteoblastsFigure 1. Gli1 Defines a Perivascular MSC-like Cell Population Residin
(A) Adult Gli1-CreERt2; tdTomato mice 48 hr after tamoxifen administration. Aort
subclavian artery (LSCA) are shown. Gli1+ cells reside in the adventitia (A) distant
Scale bars, 20 mm or as indicated.
(B and C) Gli1-tdTomato+ cells also reside adjacent to CD31+ endothelial cells
microscopy (TEM) picture of immunogold-labeled (arrows in B) Gli1+ interstitial k
shown. Gli1+ cells are PDGFRb+ (small arrowheads in C). Gli1-tdTomato+ are loca
(asterisk lung). Scale bars, 0.2 mm in (B) and 20 mm in (C).
(D) Sorted Gli1-tdTomato+ cells possess in vitro trilineage differentiation capac
adipocytes (Oilred O staining), and chrondrocytes (Alcian Blue staining). Experim
(E) Flow cytometry of whole organs demonstrates a typical MSC surface pattern
Figure S1.regardless of their origin (Figure 1D). We then performed
whole organ flow cytometry without preculture of the cells and
confirmed the expression of a typical mouse MSC marker
pattern (Boxall and Jones, 2012; Pelekanos et al., 2012) on
Gli1+ cells in vivo (Figure 1E). Importantly, Gli1+ cells were nega-
tive for the EC marker CD31 and the hematopoietic lineage
marker CD45 while we observed low levels of CD34 expression
in some organs (Figure 1E). Furthermore, we assessed the
expression of other markers that have been described for
MSCs and/or pericytes by immunostaining of tissues. We
demonstrated that Gli1+ cells do not express significant levels
of NG2, CD73, CD146, and STRO1, whereas we observed
expression of 3G5, Nestin, and PDGFRa (Figure S1D). These ex-
periments show that Gli1+ cells express typical markers and are
a source of MSC-like cells across all organs tested.
Gli1+ Cells Line the Endosteum and Vascular Sinusoids
in the Bone Marrow and Retain a Typical MSC Surface
Pattern in Culture
In the bone marrow niche, MSCs surround blood vessels and
sinusoids but also line endosteum (Morrison and Scadden,
2014). We observed Gli1+ cells lining CD31+ ECs of bonemarrow
sinusoids as well as endosteum of the compact bone (Figure 2A),
representing both the vascular and the endosteal niche.
Because mouse bone marrow MSCs in the endosteal niche
cannot readily be isolated from the bone marrow, we applied
an endosteal bone chip culture method. Interestingly, Gli1+ cells
migrated out of the bone fragments and proliferated in the cul-
ture dish (Figure 2B). Flow cytometric analysis of these cells indi-
cated that 32% had a Gli1+ origin (Figure 2C). MSCs isolated
from bone chips (BM-MSCs) or isolated from the myocardium
(heart, H-MSCs) maintained a typical MSC surface pattern with
expression of CD44, CD29, CD105, and Sca1, with an absence
of CD31, CD45, and CD34 in culture (Figures 2C and 2D).
Furthermore, Gli1+ cells from bone, heart, and kidney retained
expression of 3G5, Nestin, and PDGFRa and gained expression
of CD146 and CD73, while we did not detect significant expres-
sion of NG2 or STRO1 in culture (Figure S2). These data suggest
that Gli1+ cells in culture are similar despite their origin from
different organs.
Gli1+ Cells Represent Only a Small Fraction of the
PDGFRb+ Cell Population with Increased Colony
Forming Unit Capability
Our results indicated that Gli1 expression in adult mice defines
PDGFRb+ MSC-like perivascular cells. However, a critical ques-
tion was whether there were any functional differences betweeng as Adventitial Progenitors in the Pericyte Niche
ic root with innominate artery (IA), left common carotid artery (LCCA), and left
from CD31+ endothelial cells of the intima (I) and media (M) and are PDGFRb+.
across organs tested (EC in B and arrowheads in C). Transmission electron
idney cell adjacent to an endothelial cell (EC, asterisk in B capillary lumen) is
ted around biliary ducts (asterisk liver) and pulmonary bronchi and bronchioles
ity toward osteoblasts (alkaline phosphatase-AP + von Kossa-vKo staining),
ents were repeated at least three times; scale bars, 50 mm; AP+vKo, 100 mm.
of Gli1-tdTomato+ cells. Data are presented as mean ± SEM; n = 3. See also
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Figure 2. Gli1+ Cells Reside in a Typical MSC Niche of the Bone Marrow and Retain Their MSC Surface Pattern in Culture
(A) Gli1-tdTomato+ cells surrounding endothelial cells of bone marrow sinusoids and along the endosteum. Scale bars, 100 mm.
(B) Gli1+ cells migrating out of compact bone chips in vitro. Scale bars, 200 mm.
(C) Flow cytometry of BM-MSCs isolated from compact bone chips of Gli1-CreERt2; tdTomatomice after 4 weeks of culture, indicating that 32%of the cells are of
Gli1+ origin (tdTomato+) and maintain a typical mouse MSC surface profile.
(D) Flow cytometry of cultured (4 weeks) Gli1-tdTomato+ cells from the myocardium with a similar surface profile. Data represent at least three independent
experiments; see also Figure S2.
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whole organs indicated that all Gli1+ cells express PDGFRb, but
they represent only a small fraction of the total PDGFRb+ popu-
lation (Figure 3A).
We next askedwhether Gli1+ cells differ in their clonogenic po-
tential from Gli1PDGFRb+ and PDGFRbGli1 cells. We sorted
these populations from lung, heart, kidney, and cultured bone
chips and assessed colony formation after 2 weeks. Indeed,
the clonogenic frequency of the Gli1+PDGFRb+ fraction was
significantly higher than that of the other populations across tis-
sues tested (Figures 3B and 3C). Furthermore, colonies from the
Gli1+PDGFRb+ fraction were substantially larger (Figures 3D and
S3A). Gli1+ cells showed stable growth over many passages
in vitro (cells were grown for >30 passages from bone chips
and >10 passages from all other organs).
Gli1+ Cells Constitutively Express Gli In Vitro while
Pharmacologic Inhibition of Gli Reduces Their Colony
Forming Unit Capability
Gli1+ cells retain significant mRNA expression of most Hh
pathway members in vitro including Gli1–Gli3 (Figure S3B).54 Cell Stem Cell 16, 51–66, January 8, 2015 ª2015 Elsevier Inc.Given reported roles for Hh signaling in cell proliferation, we
next investigated whether inhibition or activation of Hh signaling
affects the CFU-F capability of Gli1+ cells. Exogenous Shh
increased Gli1 protein and colony number, and the smoothened
inhibitor cyclopamine blocked this effect, but cyclopamine alone
had no effect, arguing against autocrine Hh ligand secretion (Fig-
ures 3E and 3F). By contrast, targeting Gli directly with the small
molecule antagonist GANT61 decreased Gli1 protein levels and
also decreased CFU-F capacity (Figures 3E and 3F). These re-
sults suggest constitutive expression of Gli1 in MSC-like cells
in vitro. That direct inhibition of Gli reduced clonogenic capacity
also implicates Gli in the self-renewal of Gli1+ progenitor cells.
Perivascular Gli1+ Cells Expand and Become
Myofibroblasts after Injury of Major Organs
The MSC is most commonly defined as a cell with trilineage dif-
ferentiation capability and CFU-F capacity in vitro (Park et al.,
2012). Our results thus far suggested that Gli1+ cells in adult
mice fulfill these criteria among organs tested and additionally
express an MSC surface pattern in vivo. It has been proposed
that MSCs in the perivascular niche become activated upon
Figure 3. Gli1+ Cells Represent a Small CFU-F Enriched Fraction of the PDGFRb+ Population and Inhibition of Gli Reduces Their Self-Renewal
(A) Gli1-tdTomato+ cells represent only a small fraction of the PDGFRb+ kidney cell population.
(B) PDGFRb+, Gli1-tdTomato+ cells exhibit superior clonogenicity by CFU-F assay (>50 cells/colony at 14 days, n = 3,*p < 0.05 by t test, mean ± SEM).
(C) Gli1-tdTomato+ cells from cultured bone chip also exhibit superior clonogenicity by CFU-F assay.
(D) Colonies cultured from whole hearts 7 days after sorting.
(E) Gli1 protein level is regulated by the Hedgehog pathway in Gli1+ cells cultured from bone chips.
(F) Hedgehog pathway also regulates clonogenicicty of Gli1+ cells cultured from bone chips. cyclo, cyclopamine; Shh, Sonic Hedgehog. Scale bars, 500 mm, *p <
0.05, **p < 0.01, ***p < 0.001 by t test; mean ± SEM. See also Figure S3.
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2011). This prompted us to perform fate tracing and ablation
studies of Gli1+ cells after injury tomajor organs, including kidney
(unilateral ureteral obstruction [UUO] and severe bilateral
ischemia reperfusion injury [IRI]), heart (angiotensin-2 [AT2]-
induced myocardial fibrosis and ascending aortic constriction
[AAC]), liver (carbon tetrachloride [CCL4]-induced fibrosis) and
lung (intratracheal bleomycin instillation). To track the fate of
genetically labeled Gli1+ cells, we labeled them via tamoxifen
administration and followed their fate in various organ injury
models for up to 52 days. The injury was induced at least
10 days after tamoxifen administration to eliminate any possibil-
ity of recombination after injury (Go¨ritz et al., 2011).
In both models of kidney injury, we observed a dramatic in-
crease in Gli1+ cells in the medulla, in the the inner cortex, and
around arteries throughout the kidney and to a lower extent inthe outer cortex (Figures 4A and S4A–S4C). The proliferative
expansion and distribution of Gli1+ cells after kidney injury
suggested that they may differentiate into myofibroblasts. One
of the defining features of myofibroblasts is expression of
alpha smooth muscle actin (a-SMA), and indeed most Gli1+ cells
acquired expression of a-SMA after injury (Figure 4A and
S4A–S4C). Thus Gli1+ cells proliferate and differentiate into
myofibroblasts in kidney fibrosis.
To exclude the possibility that ‘‘leaky’’ recombination might la-
bel cells that activate Gli1 expression after injury, we performed
UUO surgery in bigenic Gli1-CreERt2; tdTomato mice without
tamoxifen injection. There was no significant recombination un-
der these conditions (Figures S4D–S4F). We also excluded the
possibility that residual tamoxifen might label Gli1+ cells after
injury by extending the time between tamoxifen administration
and UUO surgery from 10 days to 3 months. Importantly, theCell Stem Cell 16, 51–66, January 8, 2015 ª2015 Elsevier Inc. 55
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our original experiments, indicating that recombination was not
occurring after surgery (Figures S4D–S4F). We also counter-
stained fibrotic kidneys after UUO and demonstrated that indeed
all myofibroblasts (96% of a-SMA+ cells) express PDGFRb
(Figures S4H and S4I), consistent with a recent report (Hender-
son et al., 2013).
Cardiac fibrosis in the AT2-induced hypertensive heart dis-
ease model primarily affects coronary arteries and arterioles
with extensions of collagen from the perivascular space into
the cardiac interstitium (Weber et al., 1995), and this is what
was observed in Gli1-CreERt2; tdTomato mice (Figure 4B).
Fate tracing experiments revealed expansion of Gli1+ cells in
the perivascular space where the vast majority of Gli1+ cells
differentiated into a-SMA+ myofibroblasts (Figures 4B–4D). We
also used AAC surgery to induce pressure-overload heart
failure as a second model with perivascular but also interstitial
myocardial fibrosis. In this case we observed both perivascular
Gli1+ expansion but also expansion of Gli1+ cells in the cardiac
interstitium distant from arteries and arterioles (Figures 4E–4I)
that also differentiated into a-SMA+ myofibroblasts (Figures 4G
and 4I).
Large interstitial collagen 1+ fibrotic areas were entirely full of
Gli1+ cells (Figure S4J), consistent with matrix secretion by
Gli1+ cells, prompting us to ask whether Gli1+ cells mediate scar-
ring after myocardial infarction. Indeed after coronary artery liga-
tion the entire left ventricular scar area was full of a-SMA+ Gli1+
cells (Figures S4K–S4M). We next quantitated the contribution of
Gli1+ cells to the myofibroblast pool in kidney and heart. This
analysis revealed that 45% of myofibroblasts in the kidney
and60% of cardiac myofibroblasts derived from Gli1+ progen-
itors (Figure S5A). Given the significant contribution of Gli1+ cells
to the myofibroblast pool in heart and kidney, we then asked
whether Gli1+ cells also contribute to themyofibroblast pool after
liver and lung injury. Indeed, we observed significant expansion
and differentiation into a-SMA+ cells after liver and lung injury
(Figures 5A–5F). Gli1+ cells contributed to 37% of a- SMA+
interstitial cells after lung injury and 39% of interstitial
a-SMA+ cells in liver fibrosis (Figure S6G).
After injury of major organs Gli1+ cells expanded through
proliferation (Figures S6A–S6F) and themajority of Gli1+ cells ac-
quired a-SMA expression (Figures 4 and 5), suggesting that peri-
vascular Gli1+ cells are committed to the myofibroblast lineage
after injury. In line with these in vivo fate tracing studies, isolated
FACS-purified Gli1+ cells from healthy bone marrow or heart did
not express a-SMA 7 days after isolation. However, treatment
with transforming growth factor beta (TGF-b) resulted in signifi-Figure 4. After Kidney or Heart Injury Gli1+ Cells Expand and Different
(A) Genetic lineage analysis of Gli1+ cells after unilateral ureteral obstruction (UUO
(a-SMA) expression. tdTomato or a-SMA increases are measured in 4003 high po
t test; mean ± SEM.
(B–D) Myocardial fibrosis induced by angiotensin-2 (AT2, n = 4; PBS, n = 3) causes
arteries where Gli1+ cells expand and differentiate into a-SMA+ myofibroblasts. Q
500 mm; all others, 50 mm; ***p < 0.001 by t test; mean ± SEM.
(E–I) Ascending aortic constriction induces cardiac hypertrophy, fibrosis, and c
dramatically in the myocardial interstitium and acquire a-SMA expression. Quan
tdTomato and a-SMA it is important to study the perinuclear region due to a conve
panels, 500 mm; all others, 50 mm; **p < 0.05, ***p < 0.001 by t test; mean ± SEMcant upregulation of a-SMA mRNA and expression of a-SMA+
stress fibers (Figures 5G–5J).
Gli1+ Cells Do Not Express NG2 in Homeostasis or
Fibrosis but Acquire NG2 Expression during
Angiogenesis
Although not all pericytes express NG2 (Song et al., 2005; Stark
et al., 2013), NG2 has been proposed as amarker of mature peri-
cytes by some authors (Song et al., 2005). With an important role
in angiogenesis where it promotes ECmigration and proliferation
(Fukushi et al., 2004; Stallcup, 2002), NG2 expressionmay not be
static but rather induced in pericytes during angiogenesis and
microvascular remodeling (Murfee et al., 2006). By contrast,
many pericytes might show reduced or no expression of NG2
during homeostasis. In tumors, it has been demonstrated that
PDGFRb+/NG2 perivascular cells can differentiate into mature
NG2+ pericytes (Song et al., 2005). Moreover, recent work sug-
gests that during injury and repair of themouse incisor, Gli1+ pro-
genitors differentiate into NG2+ mature pericytes. Interestingly,
the authors also demonstrated that Gli1+ cells give rise to the
entire MSC population from the mouse incisor, whereas NG2+
cells only contribute a minor subpopulation (Zhao et al., 2014).
These data suggested that Gli1 expression may define immature
perivascular cells, distinct from mature NG2+ pericytes, and
constitute the major progenitor pool for MSCs. We therefore
asked whether Gli1+ cells could acquire expression of NG2
during fibrosis. Interestingly, we observed that only a small
fraction of Gli1+ cells expressed NG2 (5%) and this fraction
actually decreased after UUO or AAC (Figure S5B). Of note,
Gli1+ cells retained expression of other pericyte/MSC markers,
i.e. 3G5, PDGFRa, PDGFRb, and Nestin, during fibrosis in vivo
(Figure S5C).
Given a reported role for NG2 in angiogenesis (Fukushi et al.,
2004), we next asked whether Gli1+ cells gain NG2 expression
after myocardial infarction because angiogenesis is involved in
the repair process of this model. Indeed, we observed Gli1+ cells
expressing NG2 and CD146 assembling vascular-like structures
within the left ventricular scar after coronary artery ligation (Fig-
ure S5D). Gli1+ cells from bone chips did not express NG2
in vitro (Figure S2).We then tested whether cultured cells acquire
NG2expression and contribute to neovascularization in an in vivo
Matrigel-plug angiogenesis assay. Four weeks after implanting
Gli1+ cells, we observed developing vessels with Gli1+ cells
surrounding CD31+ ECs (Figure S5E). Gli1+ cells adjacent to
ECs acquired expression of NG2 and CD146 (Figure S5E).
These experiments suggest that Gli1+ cells acquire expression
of NG2 during angiogenesis. Because NG2 can directly bind toiate into Myofibroblasts
, n = 4). Gli1+ cells expand after UUO and acquire alpha smooth muscle actin
wer fields (hpf). Scale bars, left panel, 500 mm; all others, 50 mm; ***p < 0.001 by
hypertension-induced, predominantly perivascular fibrosis aroundmyocardial
uantification by confocal micrographs in 4003 hpf. Scale bars, left two panels,
hronic heart failure (AAC, n = 4; sham, n = 3). After AAC, Gli1+ cells expand
tification by confocal micrographs in 4003 hpf. For studying coexpression of
rse a-SMA tdTomato expression pattern (see Figure S4G). Scale bars, left two
. See also Figures S4 and S5.
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Figure 5. Fate Tracing of Gli1+ Cells in Liver and Lung Injury
(A–C) Hepatic fibrosis was induced by carbon tetrachloride injections (CCL4, n = 5; vehicle, n = 3) twice per week and the fate of Gli1-labeled cells was analyzed.
Hepatocyte necrosis (asterisk) and fibrosis was visible, with expansion of Gli1-tdTomato+ cells in fibrotic areas (arrowheads). Gli1+ cells acquired a-SMA
expression (arrows). Throughout this Figure, quantification is from confocal micrographs in 4003 hpf, in this case from periportal and pericentral fields in (B) and
(C). Scale bars, left panel, 500 mm; all others, 50 mm, ***p < 0.001 by t test; mean ± SEM.
(D–F) Pulmonary fibrosis was induced by bleomycin (n = 4) or vehicle (n = 3). Lowmagnification (left panel) shows Gli1+ expansion (quantification in E) with severe
pulmonary fibrosis (trichrome). Gli1+ cells line the peribronchial smooth muscle cell layer (arrowhead, bronchus-lumen = asterisk) of a healthy noninjured lung. In
(legend continued on next page)
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of vascular endothelial growth factor (VEGF) expression and
therefore angiogenesis (Shikada et al., 2005), these results are
also consistent with a proangiogenic role for NG2 expression
in Gli1+ MSC-like cells.
Gli Inhibition and Myofibroblast Differentiation Reduces
Gli1+ Progenitor EC Tube Association In Vitro
Hh signaling plays a critical role in angiogenesis, while detach-
ment of perivascular cells from capillaries has been proposed
as an early event triggering capillary destabilization and hypoxia
in fibrosis (Schrimpf et al., 2014). We therefore studied tube for-
mation with Gli1+ cells and ECs in 3D collagen gels in vitro. Inter-
estingly, Shh treatment increased the number of Gli1+ cells in the
gels and promoted their association with EC tubes. Inhibition of
Gli1 by GANT61 dramatically reduced the fraction of Gli1+ cells
associated with EC tubes (Figures S6H–S6K). Our previous
data demonstrate that TGF-b treatment leads to myofibroblast
differentiation of Gli1+ cells. In the tube formation assays, TGF-
b significantly reduced the fraction of Gli1+ cells adjacent to EC
tubes, whereas treatment with VEGF-165 resulted in a high frac-
tion of Gli1+ cells associated with EC tubes. These data suggest
that several pathways are important in Gli1+ progenitor/EC tube
association and that myofibroblast differentiation reduces the
association of Gli1+ cells with ECs.
Resident, but Not Circulating, Gli1+ Progenitor Cells
Contribute to Fibrosis
It has been proposed that bone-marrow-derived MSCs circulate
and home to injured kidney where they differentiate into a-SMA+
myofibroblasts (LeBleu et al., 2013). Because our results suggest
that Gli1+ cells are myofibroblast progenitors, are MSC-like, and
are located both within organs but also in the bone marrow, we
therefore asked whether Gli1+ cells circulate and home to injured
organs. While bonemarrow transplantation (BMTX) is a standard
approach to trace the fate of circulating cells, irradiation injury
may promote fibrosis and alter MSC properties, and it is unclear
whether MSCs actually engraft after BMTX (Cilloni et al., 2000).
We therefore utilized both BMTX and also parabiosis, where
two mice are conjoined and share one blood circulation, to ask
whether Gli1+ cells circulate and home to injured tissue.
Ptprca-Pepcb mice harboring the common leukocyte antigen
variant CD45.1 were lethally irradiated and received whole
bone marrow of bigenic Gli1-CreERt2; tdTomato donors
(CD45.2) that were injected with tamoxifen prior to sacrifice
and bone marrow harvest. Five weeks later, the mice underwent
UUO or sham surgery (Figure 6A). Flow cytometric analysis using
antibodies specific for the common leukocyte antigen variants
demonstrated a successful engraftment of CD45.2+ donor cells
into recipient bone marrow (Figure 6B). These engrafted
CD45.2+ donor leukocytes migrated into the kidney after UUO
surgery, as expected (Figure 6C). However, only a small number
of Gli1+ cells engrafted into bone marrow (Figures 6D and 6E),fibrosis Gli1+ cells expand into interstitium and acquire a-SMA expression (arrow
**p < 0.01, ***p < 0.001 by t test; mean ± SEM.
(G–J) Sorted Gli1+ cells from compact bone or myocardium differentiate into a-S
(TGF-b) in vitro (n = 3). Scale bars, 50 mm; *p < 0.05, ***p < 0.001 by t test; meanwhereas many more Gli1+ cells were trapped in the lung (Figures
6C–6E), consistent with previous reports (Schrepfer et al., 2007).
The number of Gli1-tdTomato+ cells between sham, contralat-
eral (CLK), or UUO kidney did not differ significantly, and impor-
tantly, no interstitial tdTomato+ cells were observed (Figures
6D and 6F). Some Gli1+ cells were also trapped in kidney
glomeruli (Figure 6F). Interestingly, Gli1+ cells persisted in the
lung >6 weeks after transplantation, with some even expressing
a-SMA (Figure 6F). These results suggest that engrafted Gli1+
donor cells do not circulate and home to the kidney nor
contribute to the myofibroblast pool after injury (UUO). Because
only a small fraction of Gli1+ cells engrafted in bone marrow,
however, we next turned to the parabiosis model to examine
Gli1+ cell circulation.
Bigenic Gli1-CreERt2; tdTomato mice received tamoxifen
and were conjoined 10 days after the last tamoxifen injection
(Figure 6G). Shared circulation was verified 4 weeks after para-
biosis surgery (Figure 6H) and UUO surgery was performed in
the Ptprca-Pepcb CD45.1+ parabiont. Mice were sacrificed
10 days later. Flow cytometric analysis of PBS perfused spleens
and kidneys showed a complete cross-circulation with CD45.1+
and CD45.2+ leukocytes in the tissue of both mice (Figures 6I–
6K). There was a significant influx of CD45.2+ leukocytes from
the Gli1-CreERt2; tdTomato parabiont in the UUO kidney of the
CD45.1+ parabiont (z17% of all kidney cells, Figures 6J and
6L), but few Gli1-tdTomato+ cells were detected in CLK or
UUO kidney of the CD45.1+ parabiont (Figures 6J and 6M).
Microscopic evaluation failed to detect any Gli1-tdTomato+ cells
in the CD45.1+ parabiont despite robust fibrosis and a-SMA+
myofibroblast expansion (Figure 6N). This experiment provides
clear evidence that neither circulating nor bone-marrow-derived
Gli1+ cells contribute to the myofibroblast pool in kidney fibrosis.
Ablation of Gli1+ Cells Ameliorates Kidney Fibrosis
To assess the functional contribution of Gli1+ cells to fibrosis,
we crossed mice with an inducible human diphtheria toxin
(DTX) receptor allele (iDTR) to Gli1-CreERt2 mice (Figure 7A).
After tamoxifen-induced recombination of the transcriptional
stop sequence, administration of DTX ablates Gli1+ cells in this
model. Tamoxifen was given to bigenic mice before UUO or
sham surgery. After surgery, mice were injected with either
DTX or vehicle (PBS) as indicated (Figure 7B). Successful abla-
tion of Gli1+ cells after UUO was verified by quantitative PCR
for DTR mRNA (Figure 7F). There was a striking reduction in kid-
ney fibrosis readouts after DTX compared to vehicle, whereas
ablation of the Gli1+ progenitor cell population in the sham group
had no appreciable effect (Figures 7C–7E and S7A–S7F).
Despite the fact that Gli1+ cells represent only 0.2% of the total
PDGFRb+ kidney cell population, their ablation after injury
reduced fibrosis dramatically by 50% (Figure S7A), indicating
that the Gli1+ population plays a critical role in regulating fibrosis
during chronic injury. To test whether our ablation approach is
specific to the Gli1+ population, we generated triple transgenics, quantification in F). Scale bars, left two panels, 500 mm; all others, 20 mm;
MA+ myofibroblasts after exposure (24 hr) to transforming growth factor beta
± SEM. See also Figures S4 and S5.
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Figure 6. Circulating Gli1+ Cells Do Not Contribute to Kidney Fibrosis
(A) Bone marrow transplantation scheme. Marrow from genetically labeled Gli1-CreERt2; tdTomato donors was transplanted into lethally irradiated, unlabeled
CD45.1 recipients. To increase the number of transplanted Gli1+ cells, we added 2 3 106 sorted Gli1+ cells from bone chips to the whole bone marrow cell
solution. After engraftment was verified, recipients underwent UUO (n = 5) or sham (n = 3) surgery.
(B) Verification of engraftment of CD45.2+ donor leukocytes into CD45.1 recipients.
(C) CD45.2+ leukocytes from Gli1-CreERt2; tdTomato donors increase in UUO kidney of the CD45.1+ recipient compared to the contralateral (CLK) or sham
kidney. Data were assessed by flow cytometry of whole digested kidneys (sham, n = 3; CLK, n = 5; UUO, n = 5). ***p < 0.001 by one way ANOVA with posthoc
Tukey.
(D) No increase in tdTomato+ cells in recipients’ kidneys 10 days after UUO (sham, n = 3; CLK, n = 5; UUO, n = 5). p values, not significant by one-way ANOVAwith
posthoc Tukey.
(E and F) tdTomato+ cell distribution in bone marrow (BM), lung, sham kidneys, contralateral kidneys (CLK), and UUO kidneys of recipients. Scale bar, left panel,
25 mm; all others, 500 mm; inserts, 50 mm.
(legend continued on next page)
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UUO ablation experiment. DTX administration substantially
decreased tdTomato+ cells, as expected (Figures S7M–S7O).
We detected apoptotic tdTomato+ cells (TUNEL+) after DTX in-
jection, yet we did not observe increased apoptosis in other renal
cell populations, providing strong evidence that DTX caused the
specific ablation of Gli1+ cells and not other cell types (Figures
S7P and S7Q).
Ablation of Gli1+ Cells Reduces Heart Fibrosis and
Rescues Left Ventricular Function after Aortic Banding
We next asked whether ablation of Gli1+ cells might improve or-
gan function during chronic disease and utilized the AAC model
of heart fibrosis with noninvasive measurement of cardiac func-
tion via echocardiography. Gli1-CreERt2; iDTR mice were in-
jected with high dose tamoxifen and subjected to AAC or
sham surgery. Mice were randomized to receive DTX or vehicle
based on their echocardiographically measured peak velocity at
the aortic suture site immediately after surgery (Figure S7H) and
their left ventricular ejection fraction (EF) at 2 weeks after sur-
gery. DTX or vehicle was given as indicated at 3 and 5 weeks af-
ter surgery (Figure 7G).
Ablation of Gli1+ cells after AAC reduced cardiac hypertrophy,
heart weight, and cardiomyocyte cross-sectional area (Figures
7G–7I). Quantitative PCR confirmed reduction of iDTR mRNA
expression by 75%, indicating successful ablation of Gli1-
iDTR+ cells (Figure 7J). Quantification of fibrotic readouts
demonstrated a remarkable reduction of interstitial myocardial
fibrosis after Gli1+ cell ablation, indicating that the perivascular
Gli1+ cell population is in fact an important driver of interstitial
myocardial fibrosis (Figures 7K–7P and S7I–S7K). Importantly,
echocardiographic analysis of left ventricular function demon-
strated that ablation of Gli1+ cells rescued chronic heart failure
after AAC by preserving left ventricular ejection fraction and
thus, myocardial function (Figures 7Q and 7R). These results
indicate not only that cardiac Gli1+ cells drive fibrogenesis in
pressure-overload heart failure, but that this process impairs
myocardial function.
DISCUSSION
Knowledge concerning the in vivo function of MSCs in special-
ized niches such as bone marrow and mouse incisor is growing
rapidly (Morrison and Scadden, 2014; Zhao et al., 2014). Thus
far, however, little is known about the in vivo role of MSCs in clin-
ically important solid organs such as kidney, heart, lung, and
liver, after injury and during repair. Here we demonstrate that(G and H) Parabiosis experimental design. After tamoxifen, Gli1-CreERt2; tdTom
circulation was verified by flow cytometric analysis of peripheral blood from the
parabiont and analyzed 10 days after surgery.
(I) Spleen chimerism for the common leukocyte antigen variants assessed by flo
(J) Flow cytometric plots of whole digested CLK and UUO kidney from the CD45
with almost no detection of tdTomato+.
(K) Chimerism for CD45.1+ versus CD45.2+ leukocytes in CLK and UUO kidneys
(L) Influx of CD45.2+ leukocytes from the Gli1-tdTomato parabiont in CLK and U
(M) Gli1-tdTomato cells do not circulate. Almost no tdTomato+ cells are detected
(N) Gli1-tdTomato+ cells are seen in the uninjured kidneys of the CD45.2 parab
despite robust fibrosis (a-SMA staining). Scale bars, top panel, 500 mm; bottom,Gli1 expression in adult mice marks a perivascular cell popula-
tion that forms an extensive network from the adventitia of large
arteries to the pericyte niche in capillary beds of all major organs
tested. These Gli1+ cells express a typical mouse MSC surface
profile in vivo, are enriched for CFU-F, and possess a trilineage
differentiation capability in vitro, therefore fulfilling the most
commonly used definition of what has been termed an MSC
(Park et al., 2012). Our data extend the recent finding that Gli1
labels MSC-like cells in the mouse incisor (Zhao et al., 2014)
and strongly suggest that Gli1 is a general in vivo marker for
MSC-like cells during adult homeostasis. Indeed, it has become
evident in recent years that the perivasculature comprising peri-
cyte and adventitial locus might be the in vivo niche of MSCs,
which would also explain why MSCs can be isolated from virtu-
ally all organs (Murray et al., 2014).
Our genetic fate tracing results indicate that resident perivas-
cular Gli1+ cells undergo proliferative expansion after injury and
differentiate into myofibroblasts in vivo. Indeed, it was noted
over a century ago that fibrosis emanates from blood vessels (At-
kins, 1875) and recent work implicates vascular pericytes as my-
ofibroblast progenitors in the kidney (Humphreys et al., 2010),
lung (Hung et al., 2013), spinal cord (Go¨ritz et al., 2011), dermis,
and skeletal muscle (Dulauroy et al., 2012). Despite this, the
contribution of pericytes to kidney fibrosis has recently been
questioned (LeBleu et al., 2013). To date, studies analyzing the
role of pericytes in solid organ fibrosis have used broad stromal
cell drivers that typically mediate recombination in several
different cell types including vascular smooth muscle cells, me-
sangial cells, resident fibroblasts, and pericytes (Asada et al.,
2011; Henderson et al., 2013; Humphreys et al., 2010; Hung
et al., 2013; LeBleu et al., 2013). A particular strength of our
work is that while PDGFRb is expressed in a relatively large
cell population across organs tested, Gli1 specifically labels a
very small subset of this cell population surrounding the macro-
vasculature and microvasculature, which we show is enriched
for CFU-F and is committed to the myofibroblast lineage after
injury.
The cellular origin of myofibroblasts in cardiac fibrosis has
been unclear for many years, although historic observations
(Maccallum, 1899) and more recent work have suggested that
perivascular cells might be involved (Weber et al., 2013), but
no fate tracing data for pericytes or perivascular cells has ex-
isted. In fact for many years it was believed that ECs were a
major source of myofibroblasts in heart fibrosis via endothelial
to mesenchymal transition (EndoMT) (Zeisberg et al., 2007). A
very recent paper implicates resident myocardial stroma as
the major source of myofibroblasts in pressure-overloadedato mice (CD45.2+) were conjoined with unlabeled (CD45.1+) mice. Shared
CD45.1+ parabiont (H, n = 8). Thereafter UUO was performed in the CD45.1+
w cytometry (n = 8 pairs, mean ± SEM).
.1+ parabiont indicating influx of leukocytes from the Gli1-tdTomato parabiont
(n = 8, mean ± SEM).
UO kidneys (n = 8, ***p < 0.001 by t test; mean ± SEM).
in the kidneys of the CD45.1 (n = 8; p, not significant by t test; mean ± SEM).
iont; however, no Gli1-tdTomato+ cells are observed in the CD45.1 parabiont
50 mm.
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were not observed (Moore-Morris et al., 2014). These latter re-
sults are consistent with our finding that resident perivascular
Gli1+ cells with distinct characteristics of MSCs differentiate
into myofibroblasts after injury of major organs including the
heart.
Matrix deposition impairs both systolic and diastolic heart
function and myofibroblasts are the main effector cells respon-
sible for this scarring in heart fibrosis. The cardiac interstitium
with fibroblasts and extracellular matrix has also been reported
to facilitate cardiac hypertrophy (Kakkar and Lee, 2010). How-
ever, whether ablation of myofibroblasts can affect scaring, hy-
pertrophy, and left ventricular function has remained unclear.
Our data clearly demonstrate that ablation of a myofibroblast
progenitor population and descendants reduces fibrosis severity
and cardiac hypertrophy and rescues systolic left ventricular
function after injury. However, our data also suggest that Gli1+
cells might gain markers of mature pericytes such as NG2 and
participate in angiogenesis. Clearly, Gli1+ cells are an intriguing
target for heart failure.
MSCs have recently been proposed by others as a source of
scar forming myofibroblasts in heart fibrosis and myelofibrosis
(Carlson et al., 2011; Schepers et al., 2013). However, this hy-
pothesis has remained speculative due to the absence of ge-
netic fate tracing data. Our results support the idea that tissue
resident perivascular MSC-like cells represent a major source
of myofibroblasts. They further suggest that under conditions
of chronic injury, MSC-like cells are not beneficial but actually
promote organ fibrosis. This might contradict the hypothesis
that MSCs act beneficially as ‘‘medicinal MSCs’’ that become
activated and promote tissue regeneration after injury (Caplan
and Correa, 2011) or the fact that exogenous infused MSCs
promote regeneration or ameliorate progression in many dis-
eases. While fibrotic scar is an adaptive response in certain
acute injuries (in myocardial infarction, for example, fibrosis
prevents left ventricular rupture), in chronic organ injury pro-
gressive myofibroblast expansion with scar deposition is path-
ologic and ultimately compromises organ function. Our resultsFigure 7. Ablation of Gli1+ Cells via the Human Diphtheria Toxin Re
Ventricular Function in Heart Failure
(A) Experimental scheme. Gli1-CreERt2; iDTR bigenic mice were administered tam
ablation of these cells via diphtheria toxin (DTX) injection.
(B) Gli1-CreERt2; iDTR mice were subjected to UUO or sham surgery and injected
sham + DTX, n = 7; UUO + VEH, n = 7; UUO + DTX, n = 8).
(C–E) Ablation of Gli1+ cells by DTX reduced severity of kidney fibrosis after UUO
for a-SMA and quantification of interstitial fibrosis. Scale bars, left two panels, 5
mean ± SEM.
(F) iDTR mRNA increases in UUO kidneys reflecting the expansion of Gli1-iDTR
kidneys, indicating ablation of Gli1-iDTR+ cells; ***p < 0.001 by t test; mean ± SE
(G) Gli1-CreERt2; iDTRmice underwent ascending aortic constriction (AAC) or sha
(DTX) (AAC, n = 9; sham, n = 5) or vehicle (PBS) (AAC, n = 10; sham, n = 5). Note
(H and I) Ablation of Gli1+ cells ameliorated cardiac hypertrophy as indicated by re
t test; mean ± SEM).
(J) Confirmation of ablation by reduction in mRNA for DTR receptor (*p < 0.05 by
(K and L) Reduced interstitial fibrosis by trichrome stain after DTX injection. Scal
(M–O)Reduced fibronectin and collagen 1 expression andquantification afterDTX
(P) Reduced a-SMA after DTX injection.
(Q and R) After AAC, vehicle-injected mice developed progressive heart failu
with significantly reduced left ventricular ejection fraction (EF) at 8 weeks. Ablation
**p < 0.01 by t test; mean ± SEM. See also Figure S6.emphasize that MSC-like cells do not always act in a beneficial
way.
Although ablation of Gli1+ cells substantially ameliorated
fibrosis in kidney and heart, we observed a-SMA+ myofibro-
blasts that do not derive from Gli1+ progenitors, suggesting a
heterogeneous lineage for the myofibroblast pool. It is striking
that Gli1+ cells reflect a very small proportion of total organ cells
and even PDGFRb+ cells but their ablation reduces fibrosis by
50% in kidney and heart. Combined with the enhanced clono-
genic capacity of Gli1+ cells compared to Gli1 interstitial cells,
these results indicate that Gli1+ MSC-like cells represent a func-
tionally distinct interstitial subcompartment. The similarity of
these cells across organs also implies a conserved response
to chronic injury culminating in fibrosis.
The precise identity of myofibroblasts in kidney fibrosis
has been a subject of considerable controversy. In contrast
with our results here, another recent study reported that neither
PDGFRb- nor NG2-expressing cells contribute to the myofibro-
blast pool in kidney fibrosis (LeBleu et al., 2013). However,
shortly after this report, another group demonstrated that
PDGFRb+ cells do indeed contribute to the myofibroblast pool
in kidney, lung, and heart fibrosis (Henderson et al., 2013).
That myofibroblasts express PDGFRb+ has been known for
many years (Asada et al., 2011; Humphreys et al., 2010; Kra-
mann et al., 2013). While the reasons for these discrepant results
are unclear, mosaic transgene expression or expression pat-
terns unfaithful to the endogenous allele, both known properties
of random integration transgenics, is one possible explanation
(Duffield, 2014; Le et al., 2006). Our results here clearly indicate
that all myofibroblasts express PDGFRb and that Gli1+ cells do
not acquire significant NG2 expression in classical fibrosis
models.
The contribution of circulating, bone-marrow-derived progen-
itor cells to the pool of myofibroblasts is also controversial
(Kramann et al., 2013) and some evidence suggests that bone-
marrow-derived MSCs enter the circulation and home to sites
of injury. Our data from BMTX and parabiosis approaches pro-
vide conclusive evidence that Gli1+ MSC-like cells are tissueceptor Ameliorates Kidney and Heart Fibrosis and Rescues Left
oxifen, leading to heritable expression of the human DTR in Gli1+cells, allowing
with vehicle (VEH = PBS) or DTX after surgery as indicated (sham + VEH, n = 5;
as demonstrated by trichrome staining, immunostaining, and western blotting
00 mm; others, 50 mm; ***p < 0.001 by one-way ANOVA with posthoc Tukey;
+-cells, whereas DTX injection significantly reduced iDTR expression in UUO
M.
m surgery andwere randomized to subsequently receive either diphtheria-toxin
decreased heart size in DTX-treated mice.
duced heart weight and cardiomyocyte (CM) cross-sectional area (*p < 0.05 by
t test; mean ± SEM).
e bars, 50 mm; ***p < 0.001 by t test; mean ± SEM.
injection. Scale bars, left panel, 500mm; right panel, 50mm; ***p < 0.001by t test.
re, as expected (representative echocardiographic M-mode pictures in Q)
of Gli1+ cells by DTX treatment rescued this progressive heart failure. *p < 0.05,
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cannot exclude a contribution from Gli1 circulating cells.
Most studies of Hh signaling during fibrosis suggest that Hh li-
gands Shh and Ihh drive myofibroblast proliferation and activa-
tion (Fabian et al., 2012; Michelotti et al., 2013). However, Hh
signaling is also critical in angiogenesis and Shh gene transfer
has been shown to reduce fibrosis and conserve left ventricular
function after myocardial ischemia, possibly reflecting Shh-
driven proangiogenic signaling in the heart (Kusano et al.,
2005). Consistent with this possibility, we found that both Shh
and VEGF increased the number of Gli1+ cells associated with
EC tubes. Shh alsomediates proangiogenic signaling by upregu-
lating VEGF expression (Pola et al., 2003; Pola et al., 2001) and
VEGF can induce expression of the Hh transcriptional activator
Gli1 (Goel and Mercurio, 2013), suggesting the possible exis-
tence of a positive feedback loop.
Our data suggest dual roles for Gli1+ cells in both fibrosis and
angiogenesis. Gli1 is a transcriptional readout of Hh pathway ac-
tivity, indicating that Gli1+ MSC-like cells respond to Hh ligand.
Consistent with this, nerve-derived Shh drives Gli1 in mouse
incisor MSCs (Zhao et al., 2014) and a similar paradigm has
been described for the hair follicle (Brownell et al., 2011).
Whether or not such a paracrine signaling loop exists for
organ resident MSC-like cells is unclear. We analyzed bigenic
ShhCreERt2+; tdTomato+ mice for expression of Shh+ cells in
adult mice, andwe did not observe any tdTomato+ cells in kidney
or heart up to 2 weeks after tamoxifen injection or after injury
(data not shown). The known roles for Gli1 in regulating cell pro-
liferation and self-renewal of stem cells suggest similar roles in
MSC-like cells (Merchant et al., 2010; Takanaga et al., 2009).
Indeed, our data points toward constitutive expression of Gli1
in Gli1+ MSC-like cells in vitro, whereas inhibition of Gli by
GANT61 reduces both self-renewal and association of Gli1+ cells
with endothelial tubes. Whether steady state Gli expression




All mouse experiments were performed according to the animal experimental
guidelines issued by the Animal Care and Use Committee at Harvard Univer-
sity. Gli1-nLacZ (JAX #008211) Gli1-CreERt2 (JAX #007913), Rosa26tdTomato
(JAX #007909) iDTR mice (JAX #007900), and Ptprca-Pepcb mice (JAX
#002014) were purchased from Jackson Laboratories. For lineage tracing
studies 6- to 7-week-old mice received 3 3 0.1 mg/kg bodyweight tamoxifen
in corn oil/3% ethanol (Sigma) via intraperitoneal injection 10 days before sur-
gery or disease induction unless otherwise stated. All models of organ injury
and cell-specific ablation experiments are described in the Supplemental
Experimental Procedures.
Bone Marrow Transplantation Experiments
Whole bone marrow was harvested from Gli1-CreERt2; tdTomato mice
(CD45.2) that had received tamoxifen injection previously. We added 2 3
106 FACS sorted Gli1-tdTomato+ cells isolated from bone chips of bigenic
Gli1-CreERt2; tdTomato mice to 3 3 106 freshly isolated whole bone marrow
cells per recipient and injected this into the tail vein of lethally irradiated
(1,050 Rads) CD45.1+ recipient mice (JAX #002014).
Parabiosis
Bigenic Gli1-CreERt2; tdTomato mice (8 weeks old) received tamoxifen (3 3
0.4 mg/kg bodyweight by gavage) and were conjoined to wild-type CD45.164 Cell Stem Cell 16, 51–66, January 8, 2015 ª2015 Elsevier Inc.mice (JAX #002014, 8 week old) 10 days after the last tamoxifen injection.
Parabiosis was performed as previously described (Ruckh et al., 2012).
Cross-circulation was confirmed by flow cytometry of peripheral blood, sple-
nocytes, and digested kidneys using antibodies specific for the common
leukocyte variants CD45.1 and CD45.2.
Gene/Protein Expression
Primers are described in Table S1 and antibodies and methods are described
in the Supplemental Experimental Procedures.
Echocardiography
Echocardiography was performed in the AAC cell-ablation experiment imme-
diately after the AAC surgery to determine the peak velocity at the constriction,
2 weeks after surgery before the randomization to DTX or Vehicle group and at
4 and 8 weeks after the surgery in low dose isoflurane anesthesia (1.5%) using
a 28 MHz linear array transducer connected to a digital ultrasound console
(Vevo 2100 Visualsonics). Images and loops were stored and analyzed offline
using the Vevo 2100 analysis software (1.6.0 Visualsonics).
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